Clinical Assessment of Breast Cancer Resistance Protein (BCRP)-Mediated Drug–Drug Interactions of Sepiapterin with Curcumin and Rosuvastatin in Healthy Volunteers
Oral coadministration of the BCRP inhibitor curcumin slightly increased the plasma exposure of sepiapterin and its metabolite BH<sub>4</sub> in healthy volunteers. This modest increase was deemed not clinically meaningful. Sepiapterin did not alter the pharmacokinetics of the BCRP substrate rosuvastatin.
Authors
- Kimberly Ingalls
- Sarah Milner (ORCID: https://orcid.org/0000-0003-2685-5296)
- Diksha Kaushik (ORCID: https://orcid.org/0000-0002-8532-5992)
- Ronald Kong (ORCID: https://orcid.org/0000-0002-4692-7499)
- Lan Gao (ORCID: https://orcid.org/0000-0002-2528-7656)
- Neil Smith (ORCID: https://orcid.org/0000-0001-8876-3958)
Institutions
- Pfeiffer Medical Center (US)
- PTC Therapeutics (United States) (US)
Publication Details
- Journal
- Drugs in R&D
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1007/s40268-024-00488-0
- Citations
- 5
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- PTC Therapeutics